Read by QxMD icon Read

Growth Hormone & IGF Research

Soraya Puglisi, Federica Spagnolo, Marta Ragonese, Salvatore Cannavò, Francesco Ferraù
The GH-receptor antagonist pegvisomant (PEG) reduces peripheral IGF-1 synthesis and is used to treat acromegaly patients resistant or intolerant to somatostatin analogues (SSA). Medical therapy is generally life-long in patients with acromegaly, since disease remission is very uncommon after SSA discontinuation and has never been reported after PEG withdrawal. Here, we report for the first time the cases of two acromegaly patients treated with PEG monotherapy for many years because of resistance to SSA, who persistently maintained normal serum IGF-1 levels after PEG withdrawal...
February 3, 2019: Growth Hormone & IGF Research
Yusuke Higashi, Sandeep Gautam, Patrick Delafontaine, Sergiy Sukhanov
Atherosclerosis is an inflammatory arterial pathogenic condition, which leads to ischemic cardiovascular diseases, such as coronary artery disease and myocardial infarction, stroke, and peripheral arterial disease. Atherosclerosis is a multifactorial disorder and its pathophysiology is highly complex. Changes in expression of multiple genes coupled with environmental and lifestyle factors initiate cascades of adverse events involving multiple types of cells (e.g. vascular endothelial cells, smooth muscle cells, and macrophages)...
January 31, 2019: Growth Hormone & IGF Research
Alev Selek, Berrin Cetinarslan, Zeynep Canturk, Ilhan Tarkun, Yusuf Hanazay, Cigdem Vural, Ihsan Anik, Savaş Ceylan
PURPOSE: Somatostatin analogues (SSAs) can slow down the growth of neuroendocrine tumors. However, the mechanism remains unclear. Recent studies on patients with acromegaly suggest that SSAs may induce apoptosis, increase autophagy, and decrease cell proliferation of pituitary adenoma. Ki-67-labeling index is a marker of cellular proliferation; therefore, decreased levels are associated with inhibition of proliferation. The aim of this study was to evaluate and compare the Ki-67-labeling index of GH-secreting pituitary adenoma tissues in patients who had undergone pituitary surgery twice due to residual or recurrent tumors and had received SSA treatment between the two surgeries...
January 30, 2019: Growth Hormone & IGF Research
Álvaro Martín-Rivada, Francisco Javier Rodríguez-Contreras, Mª Teresa Muñoz-Calvo, María Güemes, Isabel González-Casado, Jaime Sánchez Del Pozo, Ángel Campos-Barros, Jesús Argente
OBJECTIVE: We report a novel GLI2 frameshift mutation and describe the phenotypic spectrum of mutations within this gene. PATIENTS AND METHODS: A male with congenital hypopituitarism and polymalformation syndrome was clinically, biochemically and neuroradiologically characterized. Genetic analysis for congenital hypopituitarism was performed using a targeted NGS custom gene panel. RESULTS: A heterozygous frameshift mutation, NM_005270.4:c...
December 18, 2018: Growth Hormone & IGF Research
Ryan G Paul, Chris D McMahon, Marianne S Elston, John V Conaglen
OBJECTIVE: Traditional weight-based regimens of GH replacement are more effective at reversing the loss of skeletal muscle in GH-deficient adults than currently recommended regimens, where the dose of GH is increased to restore serum concentrations of IGF-1. While weight-based regimens increase concentrations of IGF-1 and decrease concentrations of myostatin, it is not known whether the reduced effectiveness of individually titrated GH regimens is due to ongoing hypersecretion of myostatin...
December 6, 2018: Growth Hormone & IGF Research
Loa Kalledsøe, Lars Ove Dragsted, Louise Hansen, Cecilie Kyrø, Henning Grønbæk, Anne Tjønneland, Anja Olsen
OBJECTIVE: Circulating levels of insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) have been associated with breast cancer (BC) risk. The evidence in relation to BC prognosis is limited. We aimed to evaluate the association between pre-diagnostic serum levels of IGF-I, IGF-II, IGFBP-2, IGFBP-3 and BC prognosis (i.e. recurrence, BC specific mortality and all-cause mortality) among women diagnosed with BC. We hypothesized that higher serum levels of IGFs and IGFBPs were associated with poor BC prognosis and that the associations were modified by estrogen receptor (ER) status...
February 2019: Growth Hormone & IGF Research
Paulo Ferrez Collett-Solberg, Alexander A L Jorge, Margaret C S Boguszewski, Bradley S Miller, Catherine Seut Yhoke Choong, Pinchas Cohen, Andrew R Hoffman, Xiaoping Luo, Sally Radovick, Paul Saenger
Short stature remains the most common reason for referral to a pediatric Endocrinologist and its management remains a challenge. One of the main controversies is the diagnosis of idiopathic short stature and the role of new technologies for genetic investigation of children with inadequate growth. Complexities in management of children with short stature includes selection of who should receive interventions such as recombinant human growth hormone, and how should this agent dose be adjusted during treatment...
February 2019: Growth Hormone & IGF Research
Julian K Christians, Neilab Amiri, John D Schipilow, Steven W Zhang, Kristyna I May-Rashke
OBJECTIVE: In humans, loss-of-function mutations in the gene encoding pregnancy-associated pregnancy protein-A2 cause short stature and slightly reduced bone density. The goal of this study was to determine the effects of Pappa2 deletion on bone in mice. DESIGN: Pappa2 deletion mice and littermate controls were culled at 10, 19 or 30 weeks of age and femurs were analysed by micro-computed tomography. Serum markers of bone turnover and insulin-like growth factor binding protein 5 (IGFBP-5), a proteolytic target of PAPP-A2, were measured by ELISA...
October 31, 2018: Growth Hormone & IGF Research
Alon Farfel, Shlomit Shalitin, Nira Morag, Joseph Meyerovitch
OBJECTIVE: Adherence to treatment regimen is a key factor in the success of Growth Hormone (GH) therapy. Our objective was to assess the long time adherence to treatment in a large cohort of patients. DESIGN: It is a retrospective study. The data was collected from a single central computerized data center well maintained and checked for quality. All patient aged 1-16 years, treated with GH during 2006-2015 for >2 years, who were insured by "Clalit" Health Maintenance Organization...
October 22, 2018: Growth Hormone & IGF Research
Bradley C Nindl, Shawn R Eagle, Ronald W Matheny, Brian J Martin, Kevin R Rarick, Joseph R Pierce, Marilyn A Sharp, Mark D Kellogg, John F Patton
OBJECTIVE: To characterize the influence of mode (aerobic/resistance) and volume of exercise (moderate/high) on circulating GH immediately post-exercise as well as following the onset of sleep. DESIGN: This study used repeated measures in which subjects randomly completed 5 separate conditions: control (no exercise), moderate volume resistance exercise (MR), high-volume resistance exercise (HR), moderate volume aerobic exercise (MA), and high volume aerobic exercise (HA)...
October 2018: Growth Hormone & IGF Research
Tharmini Sundralingam, Kamani Hemamala Tennekoon, Shamya de Silva, Sumadee De Silva, Sudeshini Hewage, Ruwandi Ranasinghe
OBJECTIVE: Characterization of a deletion in the exon 1 and 5' regulatory region of the GHRHR gene in a proband with isolated growth hormone deficiency. METHODS: Multiple ligation dependent probe amplification (MLPA) assay was carried out to confirm the homozygous deletion which was suspected during screening of the GHRHR gene by single strand conformation polymorphism. A series of short range PCR amplifications were carried out to map the approximate location of the break points of the deletion...
October 2018: Growth Hormone & IGF Research
Vaishnavi Parikh, Pardeep Gupta
Delivery of protein drugs would be an effective approach if mechanistic understanding of protein adsorption at solid/liquid surface is obtained and nonspecific adsorption can be controlled. This study involves evaluation of the thermodynamic parameters for interaction between recombinant human growth hormone (r-hGH) and nanoparticles of poly (lactic- co- glycolic) acid polymer of different molecular weight. Energy changes related to protein-nanoparticle interactions are usually very small and isothermal titration calorimetry (ITC) is the only technique that determines the binding constant (Ka), enthalpy, (ΔH) and stoichiometry, (n) in a single experiment...
October 2018: Growth Hormone & IGF Research
Yan-Qin Ying, Ling Hou, Yan Liang, Wei Wu, Xiao-Ping Luo
OBJECTIVE: This study aims to investigate the efficacy and safety of recombinant human growth hormone (rhGH) in the treatment of idiopathic short stature (ISS). METHODS: The data of 200 ISS children, who were treated with rhGH from January 2008 to December 2016, were collected and retrospectively analyzed. The data of height, bone age(BA), chronological age(CA), fasting blood glucose, fasting insulin, thyroid function and IGF-1 were collected, and annual growth velocity (GV), height standard deviation score (HtSDS) and related factors that affect GV were statistically analyzed...
October 2018: Growth Hormone & IGF Research
Sherry Zhang, Chunxia Lu, Arun K Das, Anil K Pasupulati, Ram K Menon
OBJECTIVE: To investigate the effects of GH signaling on Kupffer cells and the resulting changes in lipid homeostasis and their underlying mechanism(s) in the livers of diet-induced obese (DIO) mice. DESIGN: Male macrophage specific-growth hormone receptor knockout mice (MacGHR KO) and their litter mate controls were fed a high fat diet containing 60% calories from fat for 26 weeks. Lipid content and lipid profiles in the liver and circulation were analyzed. Expression levels of CD36 in the liver were quantified by RT-PCR and Western Blot...
October 2018: Growth Hormone & IGF Research
Ran Sawa, Hikaru Nishida, Yu Yamamoto, Ikumi Wake, Noriko Kai, Ushio Kikkawa, Yasuhiko Okimura
OBJECTIVE: Branched-chain amino acids (BCAAs) have been reported to inhibit several types of muscle atrophy via the activation of the mechanistic target of rapamycin complex 1 (mTORC1). However, we previously found that BCAA did not activate mTORC1 in growth hormone (GH)-deficient spontaneous dwarf rats (SDRs), and that GH restored the stimulatory effect of BCAAs toward the mTORC1. The objective of this study was to determine whether GH or Insulin-like growth factor-I (IGF-I) stimulated the expression of L-type amino acid transporters (LATs) that delivered BCAAs, and whether LATs were involved in the mTORC1 activation...
October 2018: Growth Hormone & IGF Research
Peter A Cattini, Margaret E Bock, Yan Jin, James A Zanghi, Hana Vakili
Human (h) pituitary growth hormone (GH) is both physiologically and clinically important. GH reaches its highest circulatory levels in puberty, where it contributes to energy homeostasis and somatogenic growth. GH also helps to maintain tissues and organs and, thus, health and homeostasis. A reduction in the rate of hGH production begins in middle age but if GH insufficiency occurs this may result in tissue degenerative and metabolic diseases. As a consequence, hGH is prescribed under conditions of GH deficiency and, because of its lipolytic activity, stimulation of hGH release has also been used to treat obesity...
October 2018: Growth Hormone & IGF Research
Silvana Duran-Ortiz, Stephen Bell, John J Kopchick
OBJECTIVE: Mice and humans with reduced growth hormone (GH) action before birth are conferred positive health- and life-span advantages. However, little work has been performed to study the effect of conditional disruption of GH action in adult life. With this as our objective, we sought to elucidate a reproducible protocol that allows generation of adult mice with a global disruption of the GH receptor (Ghr) gene, using the tamoxifen (TAM)-inducible Cre-lox system, driven by the ROSA26 enhancer/promoter...
October 2018: Growth Hormone & IGF Research
Caroline N Nelson, Edward O List, Makerita Ieremia, Lena Constantin, Yash Chhabra, John J Kopchick, Michael J Waters
OBJECTIVE: The anti-obesity actions of growth hormone (GH) led us to investigate if GH signaling is able to regulate beige/brite fat development of white adipose tissue (WAT). METHODS: We studied WAT in GHR-391 mice engineered to be unable to activate STAT5 in response to GH, in mice with adipose specific deletion of GHR, in GHR-/- mice and in bGH transgenic mice. QPCR, immunoblots and immunohistochemistry were used to characterize WAT. The in vivo effects of β-3 adrenergic activation with CL-316,243 and that of FGF21 infusion were also studied...
October 2018: Growth Hormone & IGF Research
Hannah Loher, Stefan Jenni, Julie Bucher, Marion Krüsi, Roland Kreis, Chris Boesch, Emanuel Christ
BACKGROUND: Ectopic lipids such as intramyocellular lipids (IMCL) are depleted by exercise and repleted by diet, whereas intrahepatocellular lipids (IHCL) are increased immediately after exercise. So far, it is unclear how ectopic lipids behave 24 h after exercise and whether the lack of growth hormone (GH) significantly affects ectopic lipids 24 h after exercise. METHODS: Seven male patients with growth hormone deficiency (GHD) and seven sedentary male control subjects (CS) were included...
October 2018: Growth Hormone & IGF Research
Annalaura Mastrangelo, Gabriel Á Martos-Moreno, Francisco J Rupérez, Julie A Chowen, Coral Barbas, Jesús Argente
OBJECTIVE: Mutations in the pregnancy-associated plasma protein A2 (PAPP-A2) gene have recently been shown to cause postnatal growth failure in two prepubertal patients from a non-consanguineous Spanish family due to the resulting decrease in IGF1 bioavailability. Although a specific pharmacological treatment of this entity is yet to be established, both children received progressive subcutaneous doses (40 to 120 μg/kg) of rhIGF1 twice daily for 2 years. The improvements in growth, hyperinsulinemia and bone mineral density have been previously reported...
October 2018: Growth Hormone & IGF Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"